We can expect the following in the coming weeks:
- Race is exploring low-cost collaborative preclinical studies focused on understanding the
molecular mechanism of action of Bisantrene’s heart safety profile. Advanced discussions are
underway with a leading Australian team specialising in anthracycline cardiotoxicity research.
Race expects to update the market on the outcome of these discussions in early Q2 CY 2021.
- Race has reached in principle agreement with Prof Nagler of the Chiam Sheba Medical Center (ranked 10 in the world) to undertake an open label Phase I/II combination clinical trial of Bisantrene in r/r AML patients. Trial contract details are current being finalised and Race expects to sign in early Q2 CY 2021.
We can expect the following in the coming weeks:- Race is...
-
- There are more pages in this discussion • 17,202 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.65 | $179.8K | 108.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1437 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 3313 | 1 |
View Market Depth
| Last trade - 15.58pm 03/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |